| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 32 | 2024 | 256 | 8.680 |
Why?
|
| Liver Diseases | 17 | 2024 | 366 | 4.220 |
Why?
|
| Liver Transplantation | 23 | 2025 | 1036 | 4.080 |
Why?
|
| Hypertension, Portal | 8 | 2022 | 78 | 3.090 |
Why?
|
| Hepatitis C, Chronic | 9 | 2025 | 326 | 2.670 |
Why?
|
| Liver Cirrhosis | 18 | 2024 | 832 | 2.620 |
Why?
|
| Elasticity Imaging Techniques | 7 | 2024 | 130 | 2.490 |
Why?
|
| Antiviral Agents | 10 | 2025 | 752 | 2.060 |
Why?
|
| Hepatitis B | 4 | 2016 | 160 | 1.730 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 47 | 1.710 |
Why?
|
| Cholestasis | 4 | 2022 | 153 | 1.660 |
Why?
|
| Liver | 15 | 2024 | 1743 | 1.490 |
Why?
|
| Hepatitis B Vaccines | 3 | 2016 | 42 | 1.460 |
Why?
|
| Hepatitis B virus | 3 | 2015 | 130 | 1.290 |
Why?
|
| Child | 58 | 2025 | 24384 | 1.260 |
Why?
|
| Esophageal and Gastric Varices | 4 | 2022 | 65 | 1.200 |
Why?
|
| End Stage Liver Disease | 4 | 2025 | 181 | 1.200 |
Why?
|
| Sofosbuvir | 2 | 2025 | 14 | 1.190 |
Why?
|
| Gastroenterology | 4 | 2024 | 201 | 1.140 |
Why?
|
| Aspartate Aminotransferases | 5 | 2024 | 82 | 1.060 |
Why?
|
| Adenovirus Infections, Human | 2 | 2023 | 50 | 1.000 |
Why?
|
| Child, Preschool | 34 | 2025 | 14004 | 0.970 |
Why?
|
| Dientamoeba | 1 | 2025 | 1 | 0.960 |
Why?
|
| Dientamoebiasis | 1 | 2025 | 4 | 0.960 |
Why?
|
| Hepatitis C | 3 | 2020 | 366 | 0.950 |
Why?
|
| Cyclopropanes | 2 | 2025 | 68 | 0.900 |
Why?
|
| Ribavirin | 2 | 2025 | 79 | 0.900 |
Why?
|
| Carbamates | 2 | 2024 | 60 | 0.890 |
Why?
|
| Hepacivirus | 6 | 2024 | 244 | 0.880 |
Why?
|
| Transplant Recipients | 3 | 2021 | 217 | 0.870 |
Why?
|
| Humans | 88 | 2025 | 125085 | 0.800 |
Why?
|
| Portal Vein | 3 | 2022 | 94 | 0.760 |
Why?
|
| Perioperative Care | 3 | 2021 | 195 | 0.760 |
Why?
|
| Severity of Illness Index | 13 | 2024 | 2905 | 0.750 |
Why?
|
| Sulfonamides | 2 | 2021 | 270 | 0.750 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 89 | 0.750 |
Why?
|
| Biliary Atresia | 3 | 2022 | 190 | 0.730 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2022 | 56 | 0.730 |
Why?
|
| Gastroenteritis | 2 | 2024 | 349 | 0.710 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 11 | 0.690 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 18 | 0.690 |
Why?
|
| Uracil | 1 | 2020 | 14 | 0.690 |
Why?
|
| Anilides | 1 | 2020 | 49 | 0.680 |
Why?
|
| Immunosuppressive Agents | 4 | 2025 | 650 | 0.670 |
Why?
|
| Proline | 1 | 2020 | 78 | 0.670 |
Why?
|
| Ritonavir | 1 | 2020 | 54 | 0.660 |
Why?
|
| Lung Transplantation | 3 | 2024 | 322 | 0.650 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 179 | 0.630 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2018 | 19 | 0.610 |
Why?
|
| Adolescent | 26 | 2025 | 19349 | 0.600 |
Why?
|
| Neonatal Screening | 4 | 2021 | 184 | 0.600 |
Why?
|
| Liver Neoplasms | 5 | 2023 | 1314 | 0.580 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2015 | 51 | 0.580 |
Why?
|
| Infant | 26 | 2025 | 12475 | 0.580 |
Why?
|
| Waiting Lists | 2 | 2016 | 227 | 0.570 |
Why?
|
| Vibrio cholerae | 2 | 2018 | 26 | 0.560 |
Why?
|
| Cholera | 2 | 2018 | 25 | 0.560 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 79 | 0.560 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 241 | 0.550 |
Why?
|
| Male | 41 | 2025 | 61465 | 0.550 |
Why?
|
| Pediatrics | 6 | 2024 | 1150 | 0.550 |
Why?
|
| Female | 40 | 2025 | 66744 | 0.520 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 30 | 0.520 |
Why?
|
| Platelet Count | 7 | 2024 | 136 | 0.510 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 389 | 0.480 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2015 | 107 | 0.480 |
Why?
|
| Biomarkers | 7 | 2024 | 3081 | 0.470 |
Why?
|
| Diarrhea | 2 | 2024 | 317 | 0.470 |
Why?
|
| Weight Gain | 1 | 2017 | 400 | 0.450 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2022 | 226 | 0.440 |
Why?
|
| Hepatitis B Antibodies | 1 | 2013 | 24 | 0.440 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1169 | 0.440 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 41 | 0.430 |
Why?
|
| Postoperative Complications | 5 | 2025 | 3071 | 0.430 |
Why?
|
| O Antigens | 1 | 2013 | 9 | 0.420 |
Why?
|
| Cholera Vaccines | 1 | 2013 | 5 | 0.420 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 128 | 0.420 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 79 | 0.410 |
Why?
|
| Fatty Liver | 2 | 2019 | 187 | 0.410 |
Why?
|
| Biopsy | 4 | 2023 | 1236 | 0.400 |
Why?
|
| Treatment Outcome | 17 | 2025 | 12388 | 0.390 |
Why?
|
| Sirolimus | 1 | 2014 | 227 | 0.390 |
Why?
|
| Risk Factors | 11 | 2025 | 10285 | 0.390 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 702 | 0.350 |
Why?
|
| Body Height | 3 | 2017 | 215 | 0.340 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 57 | 0.340 |
Why?
|
| Graft Survival | 3 | 2025 | 535 | 0.340 |
Why?
|
| Alanine Transaminase | 2 | 2020 | 157 | 0.330 |
Why?
|
| Dysbiosis | 2 | 2021 | 122 | 0.320 |
Why?
|
| Registries | 5 | 2025 | 1432 | 0.320 |
Why?
|
| Retrospective Studies | 15 | 2025 | 16326 | 0.320 |
Why?
|
| Graft Rejection | 2 | 2025 | 588 | 0.320 |
Why?
|
| Hepatomegaly | 1 | 2009 | 21 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 5174 | 0.310 |
Why?
|
| Feces | 3 | 2022 | 727 | 0.310 |
Why?
|
| Failure to Thrive | 1 | 2009 | 90 | 0.300 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 307 | 0.300 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 398 | 0.290 |
Why?
|
| Mass Screening | 1 | 2013 | 785 | 0.290 |
Why?
|
| Infant, Newborn | 9 | 2023 | 8205 | 0.280 |
Why?
|
| Body Weight | 3 | 2017 | 989 | 0.280 |
Why?
|
| Prospective Studies | 11 | 2025 | 6153 | 0.270 |
Why?
|
| Young Adult | 6 | 2025 | 9052 | 0.270 |
Why?
|
| Prevalence | 4 | 2025 | 2452 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 731 | 0.260 |
Why?
|
| Fibrosis | 3 | 2023 | 434 | 0.260 |
Why?
|
| Nutritional Status | 3 | 2019 | 314 | 0.260 |
Why?
|
| Time Factors | 4 | 2019 | 6327 | 0.250 |
Why?
|
| Drug Combinations | 2 | 2024 | 267 | 0.250 |
Why?
|
| Cohort Studies | 7 | 2024 | 4814 | 0.250 |
Why?
|
| Growth Disorders | 2 | 2020 | 209 | 0.250 |
Why?
|
| Utah | 1 | 2025 | 47 | 0.240 |
Why?
|
| United States | 7 | 2025 | 10913 | 0.230 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2024 | 8 | 0.230 |
Why?
|
| Mesalamine | 1 | 2024 | 6 | 0.230 |
Why?
|
| Disease Progression | 3 | 2020 | 2062 | 0.230 |
Why?
|
| Paracentesis | 1 | 2024 | 16 | 0.230 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 26 | 0.220 |
Why?
|
| Benzimidazoles | 2 | 2024 | 133 | 0.220 |
Why?
|
| Genotype | 3 | 2024 | 2562 | 0.220 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 43 | 0.220 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 760 | 0.220 |
Why?
|
| Community Health Workers | 1 | 2024 | 66 | 0.220 |
Why?
|
| Gastrostomy | 1 | 2024 | 86 | 0.220 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2021 | 77 | 0.210 |
Why?
|
| Frailty | 1 | 2025 | 106 | 0.210 |
Why?
|
| Endoglin | 1 | 2022 | 21 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2024 | 223 | 0.200 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 21 | 0.200 |
Why?
|
| Ultrasonography | 5 | 2021 | 940 | 0.200 |
Why?
|
| Adenoviruses, Human | 1 | 2022 | 81 | 0.190 |
Why?
|
| Enzyme Replacement Therapy | 2 | 2021 | 17 | 0.190 |
Why?
|
| Age Factors | 3 | 2015 | 2817 | 0.190 |
Why?
|
| Wechsler Scales | 1 | 2022 | 20 | 0.190 |
Why?
|
| Hepatitis | 1 | 2022 | 57 | 0.190 |
Why?
|
| Varicose Veins | 1 | 2022 | 29 | 0.190 |
Why?
|
| Interleukin-8 | 1 | 2022 | 209 | 0.190 |
Why?
|
| Patient Readmission | 1 | 2025 | 385 | 0.190 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2024 | 206 | 0.190 |
Why?
|
| Pyrrolidines | 1 | 2021 | 36 | 0.180 |
Why?
|
| Quinoxalines | 1 | 2021 | 39 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1584 | 0.180 |
Why?
|
| Prognosis | 4 | 2020 | 4637 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 280 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 465 | 0.170 |
Why?
|
| 2-Naphthylamine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 4 | 0.170 |
Why?
|
| Tablets | 1 | 2020 | 27 | 0.170 |
Why?
|
| Metagenome | 1 | 2021 | 149 | 0.170 |
Why?
|
| Logistic Models | 2 | 2015 | 1807 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 23 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 183 | 0.170 |
Why?
|
| Adult | 8 | 2025 | 29628 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 269 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 141 | 0.170 |
Why?
|
| Anthropometry | 2 | 2018 | 197 | 0.170 |
Why?
|
| Adenoviridae | 1 | 2023 | 604 | 0.170 |
Why?
|
| Valine | 1 | 2020 | 115 | 0.170 |
Why?
|
| Breast Feeding | 2 | 2022 | 220 | 0.170 |
Why?
|
| Quality of Life | 3 | 2024 | 1939 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1267 | 0.160 |
Why?
|
| Bangladesh | 2 | 2024 | 22 | 0.160 |
Why?
|
| Chloride Channel Agonists | 1 | 2019 | 3 | 0.160 |
Why?
|
| Ursodeoxycholic Acid | 2 | 2018 | 37 | 0.160 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1327 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2021 | 192 | 0.160 |
Why?
|
| Neoplasms | 1 | 2013 | 2791 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 293 | 0.160 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 191 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3423 | 0.150 |
Why?
|
| Curriculum | 1 | 2024 | 726 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 293 | 0.150 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 167 | 0.150 |
Why?
|
| Pseudomonas Infections | 2 | 2019 | 114 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2018 | 208 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 389 | 0.150 |
Why?
|
| Age Distribution | 1 | 2019 | 417 | 0.150 |
Why?
|
| Desiccation | 1 | 2018 | 44 | 0.140 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 34 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 337 | 0.140 |
Why?
|
| Serologic Tests | 1 | 2018 | 118 | 0.140 |
Why?
|
| Immunoglobulin M | 2 | 2020 | 212 | 0.140 |
Why?
|
| Middle Aged | 5 | 2025 | 26919 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 187 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2021 | 1506 | 0.140 |
Why?
|
| Thrombosis | 1 | 2022 | 525 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 443 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2018 | 142 | 0.140 |
Why?
|
| Obesity | 1 | 2008 | 2247 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2019 | 300 | 0.130 |
Why?
|
| Growth | 1 | 2017 | 106 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 55 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 355 | 0.130 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 59 | 0.130 |
Why?
|
| Survival Rate | 2 | 2019 | 2061 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 1357 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 737 | 0.130 |
Why?
|
| Hepatitis D | 1 | 2015 | 3 | 0.130 |
Why?
|
| Critical Care | 1 | 2021 | 657 | 0.130 |
Why?
|
| Child Development | 2 | 2018 | 266 | 0.120 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2017 | 193 | 0.120 |
Why?
|
| Telecommunications | 1 | 2015 | 20 | 0.120 |
Why?
|
| Parenteral Nutrition | 1 | 2017 | 194 | 0.120 |
Why?
|
| Pancreas | 1 | 2016 | 221 | 0.120 |
Why?
|
| Birth Weight | 1 | 2017 | 345 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 542 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 699 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 777 | 0.120 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 93 | 0.120 |
Why?
|
| Creatinine | 1 | 2016 | 389 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 382 | 0.120 |
Why?
|
| Work | 1 | 2014 | 12 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 164 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 526 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2015 | 230 | 0.110 |
Why?
|
| Mercaptopurine | 1 | 2013 | 71 | 0.110 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6596 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 374 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1020 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 87 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 930 | 0.100 |
Why?
|
| Gestational Age | 1 | 2017 | 1161 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 71 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 363 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 581 | 0.100 |
Why?
|
| Vaccines, Inactivated | 1 | 2013 | 145 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2024 | 1195 | 0.100 |
Why?
|
| Immunoglobulin A | 1 | 2013 | 207 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 240 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 184 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2013 | 480 | 0.100 |
Why?
|
| Aged | 3 | 2025 | 19859 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2018 | 835 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2014 | 262 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2023 | 112 | 0.090 |
Why?
|
| Family | 1 | 2014 | 567 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2020 | 3456 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1421 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1025 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2054 | 0.090 |
Why?
|
| Pruritus | 2 | 2022 | 41 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 1563 | 0.080 |
Why?
|
| Glycogen Storage Disease | 1 | 2009 | 9 | 0.080 |
Why?
|
| Philadelphia | 1 | 2009 | 26 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2169 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1894 | 0.080 |
Why?
|
| ROC Curve | 2 | 2021 | 569 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2009 | 53 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 731 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3298 | 0.070 |
Why?
|
| Hospitalization | 3 | 2021 | 1779 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2426 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 783 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1142 | 0.060 |
Why?
|
| Neutropenia | 2 | 2020 | 200 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3587 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2025 | 51 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2024 | 26 | 0.060 |
Why?
|
| Benzopyrans | 1 | 2024 | 20 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 110 | 0.060 |
Why?
|
| Sustained Virologic Response | 1 | 2024 | 41 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2023 | 51 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2022 | 15 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 52 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 47 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 128 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 86 | 0.050 |
Why?
|
| Bilirubin | 1 | 2022 | 122 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 367 | 0.050 |
Why?
|
| Trachea | 1 | 2023 | 202 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2021 | 103 | 0.050 |
Why?
|
| Self Report | 1 | 2024 | 518 | 0.050 |
Why?
|
| Constipation | 1 | 2022 | 113 | 0.050 |
Why?
|
| Genotyping Techniques | 1 | 2021 | 103 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 190 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2021 | 62 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2021 | 49 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 762 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1637 | 0.040 |
Why?
|
| Health Status | 1 | 2022 | 376 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 98 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 276 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 186 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 173 | 0.040 |
Why?
|
| Body Size | 1 | 2020 | 55 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 117 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 494 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1110 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 517 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 537 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 226 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2019 | 50 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2019 | 69 | 0.040 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.040 |
Why?
|
| Sudan | 1 | 2018 | 4 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 25 | 0.040 |
Why?
|
| Cough | 1 | 2019 | 91 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 29 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 191 | 0.040 |
Why?
|
| beta Carotene | 1 | 2018 | 41 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 423 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 216 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 3141 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 593 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 666 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2024 | 1003 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 601 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1436 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 273 | 0.030 |
Why?
|
| Uzbekistan | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 2015 | 6 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 873 | 0.030 |
Why?
|
| Ukraine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 277 | 0.030 |
Why?
|
| Sclerotherapy | 1 | 2015 | 40 | 0.030 |
Why?
|
| Ligation | 1 | 2015 | 134 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1105 | 0.030 |
Why?
|
| Head | 1 | 2015 | 103 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 175 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 656 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1697 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 171 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 1502 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 35 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 50 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 20 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 107 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 42 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 40 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1758 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 281 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 71 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1444 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3728 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3570 | 0.020 |
Why?
|
| Methotrexate | 1 | 2013 | 337 | 0.020 |
Why?
|
| Lung | 1 | 2019 | 1498 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 577 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 519 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4392 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1179 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 696 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1254 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 5848 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 17634 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 34219 | 0.010 |
Why?
|